An Open-Label, Dose Escalation, Pilot Study to Assess the Safety and Efficacy of Subcutaneous RG1068 (Synthetic Human Secretin) in Patients With Obsessive Compulsive Disorder (OCD)
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2006
At a glance
- Drugs Secretin (Primary)
- Indications Obsessive-compulsive disorders
- Focus Adverse reactions
- 14 Jul 2006 Status changed from recruiting to completed.
- 17 Dec 2005 New trial record.